Drug Profile
Research programme: drug and vaccine therapeutics - Pharmsynthez/Xenetic Biosciences
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Lipoxen Technologies; Pharmsynthez
- Developer Pharmsynthez; Xenetic Biosciences
- Class Cancer vaccines; Vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Cystic fibrosis; HIV infections; Multiple sclerosis; Non-Hodgkin's lymphoma; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Russia
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in Russia
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Russia (Liposomal)